Table 3. Population prevalence of copy no. in the pretreatment and reinfecting (posttreatment) isolates.
| Category | Mefloquine | Mefloquine plus artesunatea | Artemether-lumefantrineb | Artemisinin monotherapyc,d |
|---|---|---|---|---|
| Pretreatment | ||||
| Single | 1 (100) | 13 (68) | 7 (41) | 6 (55) |
| Increased | 0 (0) | 6 (32) | 10 (59) | 5 (45) |
|
| ||||
| New infections | ||||
| Single | 0 (0) | 7 (37) | 2 (12) | 3 (27) |
| Increased | 1 (0) | 12 (63) | 15 (88) | 8 (73) |
|
| ||||
| Total | 1 | 19 | 17 | 11 |
NOTE. Data are no. (%) of isolates. Paired proportions for each treatment group were compared using McNemar’s test to determine the rates of change in copy no. (single to amplified vs. amplified to single).
a
P = .15.
b
P = .06.
c
P = .38.
d
Artesunate or artemether at 12 mg/kg over 7 days.